Return to search results.
Complete title: Multicenter Selective Lymphadenectomy Trial II (MSLT II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node
|Research Study Number||7108|
|Principal Investigator||David Byrd, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Melanoma; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.